Fortitude Advisory Group’s iBio IBIO Stock Holding History

Fortitude Advisory Group’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2	Closed	–	–	681
2022 Q1	$0	Hold	2	–	–	﹤0.01%	1551
2021 Q4	$1K	Buy	+2	New	+$763	﹤0.01%	1485

Other funds holding IBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fortitude Advisory Group's IBIO Position: Q2 2022 in Review

Fortitude Advisory Group sold out of iBio (IBIO) in Q2 2022, closing a stake of 2 shares.

Fortitude Advisory Group first reported a position in IBIO in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q4 2021. 53 funds tracked by Wall St. Rank hold IBIO as of Q2 2022.

Fortitude Advisory Group reported no remaining iBio position as of Q2 2022 after selling out during the quarter.
Fortitude Advisory Group sold 2 iBio shares in Q2 2022.
Fortitude Advisory Group first reported a position in iBio in Q4 2021 and held it in 2 quarters.
Fortitude Advisory Group's iBio position peaked at $1K in Q4 2021.
53 funds tracked by Wall St. Rank held iBio as of Q2 2022.

Based on Fortitude Advisory Group's 13F filing for Q2 2022, filed 16 Aug 2022.